PR Newswire Clinical TrialsOriginal article
Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
Phase 3AP301Positive
AI Analysis
Summary
Alebund Pharmaceuticals announced completion of patient enrollment in its global Phase III pivotal trial of AP301 for hyperphosphatemia treatment. The milestone represents progress toward potential regulatory submission for this renal disease therapy.
Clinical Trial Data
Phase
Phase 3
Outcome Details
Patient enrollment completed in global Phase III pivotal multi-regional clinical trial
Importance:6/10
Sentiment:
0.50
Phase 3hyperphosphatemiarenal diseasepatient enrollmentclinical trial milestone
Read the original article
Published by PR Newswire Clinical Trials on May 6, 2026 4:00 AM